Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.
Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.
The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.
The company's shares were down 4.2% in recent trading.
Price: 1.61, Change: -0.07, Percent Change: -4.17
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。